| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | January 5, 2023 |
| Accession Number: | 0001193125-23-000327 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/11/2022 | $22.00 | Buy | Chardan Capital Markets |
| 7/18/2022 | $20.00 | Buy | H.C. Wainwright |
| 11/9/2021 | $30.00 → $23.00 | Overweight → Neutral | JP Morgan |
Submission status for OYSTER POINT PHARMA INC's drug TYRVAYA (ORIG-1) with active ingredient VARENICLINE has changed to 'Approval' on 10/15/2021. Application Category: NDA, Application Number: 213978, Application Classification: Type 3 - New Dosage Form
Chardan Capital Markets initiated coverage of Oyster Point Pharma with a rating of Buy and set a new price target of $22.00
H.C. Wainwright initiated coverage of Oyster Point Pharma with a rating of Buy and set a new price target of $20.00
JP Morgan downgraded Oyster Point Pharma from Overweight to Neutral and set a new price target of $23.00 from $30.00 previously
15-12G - Oyster Point Pharma, Inc. (0001720725) (Filer)
8-K/A - Oyster Point Pharma, Inc. (0001720725) (Filer)
EFFECT - Oyster Point Pharma, Inc. (0001720725) (Filer)